Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 8/20 | 0.55 |
| ▸ | LPL | P06858 | 2/20 | 0.50 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8528 | 0.80 | ENPP2 (0.61) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL12793048 | 0.77 | ENPP2 (0.56) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL19492760 | 0.77 | ENPP2 (0.56) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL5872608 | 0.77 | ENPP2 (0.72) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL3724201 | 0.77 | ENPP2 (0.60) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL14042197 | 0.77 | IDO1 (0.58) | KDM4E | |
| SCHEMBL522289 | 0.76 | ENPP2 (0.55) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL6359054 | 0.75 | ALDH1A1 (0.58) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL19492498 | 0.75 | LPL (0.57) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL2557515 | 0.75 | ENPP2 (0.56) | ENPP2LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180125798-A1 | Compounds and Methods for Modulating Serotonin Receptors in the Periphery | NORTHEASTERN UNIVERSITY | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125798-A1 | Compounds and Methods for Modulating Serotonin Receptors in the Periphery | HTR5A, HTR3A, HTR1A | ENPP2 327/4885LPL 659/4885LIPG 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.